The ATTIRE (Albumin to Prevent Infection in Chronic Liver Failure) trial involving IV albumin administration in hospitalized patients targeting albumin >3 g/dL showed that it did not improve outcomes; however, it increased the risks of AKI and pulmonary edema [52]. This evidence concerns the gene ALB and acute kidney injury.